Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tryptophanyl-tRNA synthetases
US-9399770-B2 · Jul 26, 2016 · US
Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of tryptophanyl tRNA synthetases
US10563191B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10563191-B2 |
| Application number | US-201615179714-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 10, 2016 |
| Priority date | Oct 6, 2010 |
| Publication date | Feb 18, 2020 |
| Grant date | Feb 18, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
First claim
Opening claim text (preview).
We claim: 1. A pharmaceutical composition, comprising an isolated polynucleotide that encodes an aminoacyl-tRNA synthetase (AARS) polypeptide, wherein the AARS polypeptide is up to 160 amino acids in length and comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:56, wherein the polynucleotide is selected from (a) a cDNA polynucleotide and (b) a modified mRNA polynucleotide, wherein the AARS polypeptide has an extracellular signaling activity, and wherein the composition is substantially endotoxin-free. 2. The pharmaceutical composition of claim 1 , wherein the AARS polypeptide consists of the amino acid sequence of SEQ ID NO: 56. 3. The pharmaceutical composition of claim 1 , wherein the AARS polypeptide is up to 160 amino acids in length and comprises the amino acid sequence of SEQ ID NO:56. 4. The pharmaceutical composition of claim 1 , wherein the AARS polypeptide is fused to a heterologous polypeptide. 5. The pharmaceutical composition of claim 4 , wherein the heterologous polypeptide is selected from the group consisting of purification tags, epitope tags, targeting sequences, signal peptides, membrane translocating sequences, and pharmacokinetic (PK) property modifiers. 6. The pharmaceutical composition of claim 1 , wherein the isolated polynucleotide comprises one or more transcriptional and/or translational control elements. 7. The pharmaceutical composition of claim 1 , wherein the modified mRNA polynucleotide comprises at least one modified base. 8. The pharmaceutical composition of claim 1 , wherein the isolated polynucleotide is formulated for delivery encapsulated in a lipid particle, a liposome, a vesicle, a nanosphere, or a nanoparticle. 9. The pharmaceutical composition of claim 1 , which is suitable for intravenous administration.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Immunosuppressants, e.g. drugs for graft rejection · CPC title
Immunomodulators · CPC title
Drugs for immunological or allergic disorders · CPC title
Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10563191B2 cover?
- Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
- Who is the assignee on this patent?
- Atyr Pharma Inc, Pangu Biopharma Ltd
- What technology area does this patent fall under?
- Primary CPC classification C12N9/93. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).